Changeflow GovPing Pharma & Drug Safety Supplement bioavailability enhancement composit...
Routine Notice Added Final

Supplement bioavailability enhancement composition patent grant

Favicon for changeflow.com ChangeBridge: Patent Grants - Pharma (A61K)
Published March 31st, 2026
Detected March 31st, 2026
Email

Summary

USPTO granted Patent No. US12589152B2 to The LIV Group Inc. for a composition combining target supplements with rehydration formulations to enhance bioavailability and absorption rates. The patent, invented by Brandin Besore Cohen and Hayden Andrew Fulstone, covers 19 claims and was filed on December 16, 2022.

What changed

USPTO granted Patent No. US12589152B2 to The LIV Group Inc. covering a composition for enhanced absorption of supplements. The composition includes at least one target supplement and a rehydration formulation that enhances bioavailability, allowing faster and greater absorption compared to ingesting the supplement separately. The composition also provides faster hydration. CPC classifications span A61K pharmaceutical preparations, A23L food/dietary supplements, and A61P therapeutic applications including neurological uses.

This is a patent grant notice providing intellectual property protection, not a regulatory action imposing compliance obligations. No deadlines, required actions, or penalties apply. Entities in the pharmaceutical, supplement, and healthcare industries may reference this patent for freedom-to-operate considerations or competitive intelligence.

Source document (simplified)

← USPTO Patent Grants

Composition for enhanced absorption of supplements

Grant US12589152B2 Kind: B2 Mar 31, 2026

Assignee

The LIV Group Inc.

Inventors

Brandin Besore Cohen, Hayden Andrew Fulstone

Abstract

A composition that includes at least one target supplement and at least one rehydration formulation is described. When the at least one target supplement is ingested as part of the composition, the bioavailability of at least one target supplement is enhanced as compared to when it is ingested separate from the composition. The at least one target supplement is absorbed more quickly and in a greater amount when it is ingested as part of the composition than when it is ingested separate from the composition. The composition also hydrates a subject more quickly.

CPC Classifications

A61K 47/02 A61K 9/0014 A61K 9/0021 A61K 9/127 A61K 31/16 A61K 31/4045 A61K 31/405 A61K 36/84 A61K 47/12 A61K 31/198 A61K 36/185 A61K 47/26 A23L 33/105 A23L 33/125 A23L 33/15 A23L 33/16 A23L 33/10 A23L 33/17 A61P 25/00 A23V 2002/00 A23V 2200/31

Filing Date

2022-12-16

Application No.

18067681

Claims

19

View original document →

Named provisions

Abstract Claims CPC Classifications

Source

Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
USPTO
Published
March 31st, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US12589152B2

Who this affects

Applies to
Drug manufacturers Healthcare providers Investors
Industry sector
3254 Pharmaceutical Manufacturing 3114 Food & Beverage Manufacturing 6211 Healthcare Providers
Activity scope
Patent Grant
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Topics
Consumer Protection Healthcare

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: Patent Grants - Pharma (A61K) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.